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Abstract
Studies indicate that inhibiting a single signaling pathway or one single product of a gene is insufficient for the prevention 
and treatment of cancer. This is due to the fact that dysregulation must occur in more than 500 genes in order to produce a 
cancerous phenotype. Despite this evidence, available drugs used for cancer treatment focus on a single target. Meanwhile, 
berberine as a nutraceutical is capable of targeting various processes involved in tumor development including proliferation, 
invasion, angiogenesis, and metastasis. In comparison with synthetic agents, berberine is cheaper, safer, and more available. 
Berberine has shown anti-inflammatory properties which make it an ideal option in order to prevent inflammation-associated 
cancers. Colorectal cancer is one of the most common cancers all over the world and its incidence is increasing each day. 
Therefore, further investigations about berberine could be helpful in the discovery of novel agents for preventing and/or 
treating colorectal cancer. This review emphasizes the studies investigating the roles of berberine in colorectal cancer such 
as controlling cell signaling pathways, inducing apoptosis, regulating microRNAs, attenuating oxidative stress, and affect-
ing inflammation.
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Abbreviations
CRC  Colorectal cancer
miRNA  MicroRNA
NF-κB  Nuclear factor-κB
IBD  Inflammatory bowel disease
IMCE  Immorto-min colonic epithelial
AIF  Apoptosis-inducing factor
ROS  Reactive oxygen species
PARP  Poly (ADP-ribose) polymerase
lncRNAs  Long non-coding RNAs
CASC2  Cancer susceptibility candidate 2
Introduction
Colorectal cancer (CRC) is the fourth cause of cancer-related 
death and the third most common cancer all over the world 
[1]. Moreover, the incidence rate of this cancer is increasing 
[1]. While colon and rectum are two parts of the gastroin-
testinal system where the CRC occurs, in most of the cases, 
this cancer involves the sigmoid colon [2, 3]. Adenomatous 
polyps or adenomas slowly lead to a large number of CRCs 
[4]. Due to the high rate of intestinal epithelium turnover, it 
is a potential hotspot for the formation of malignancies such 
as CRC [5]. At first, it was believed that genetic factors are 
responsible for morphological tissue alterations but nowa-
days, many investigations have shown that this disease can 
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also be acquired [6]. 90–95% of all cancers are attributed to 
lifestyle and environment [7]. Meanwhile, genetic factors are 
only responsible for 5–10% of cancers [7]. Evidence sug-
gests that a higher intake of fruits and vegetables lead to a 
reduced risk of various cancers including esophageal cancer, 
gastric cancer, and CRC [8, 9]. Data have shown that approx-
imately 35% of cancer-related deaths are associated with diet 
[7]. In addition, it is estimated that a remarkable number of 
new cancer cases are associated with suboptimal diet [10]. 
A large number of studies concerned with the role of diet 
and food consumption in cancers of the lung [11], breast 
[12], prostate [13], skin [14], and gastrointestinal tract [15].
Since interruption in the regulation of more than 500 
genes is needed to cause a cancerous phenotype in cell sign-
aling pathways, inhibiting one of these signaling pathways 
or a single gene product would neither prevent nor treat can-
cers [16]. In spite of this fact, most of the drugs which are 
currently used to treat cancers focus on a single target [16]. 
Thus, nowadays, a combination of multiple drugs having one 
target or design drugs modulating several targets is the para-
digm for anti-cancer therapies [16]. Nutraceuticals which 
are plant-derived dietary agents have been shown to have 
multi-targeting features [16]. In comparison with synthetic 
agents, nutraceuticals are cheaper, safer and more readily 
available [16]. Any substance which is a food or part of 
food with medical and health benefits can be considered as 
a nutraceutical [17]. There are various nutraceuticals target-
ing multiple steps in the development of tumor cells [18]. 
Some of these nutraceuticals are allicin, apigenin, berber-
ine, celastrol, curcumin and quercetin [19]. These agents are 
involved in different cancer mechanisms including survival, 
proliferation, invasion, angiogenesis, and metastasis [19, 
20]. In addition, nutraceuticals modulate nuclear factor-κB 
(NF-κB) which is an important inflammatory transcription 
factor [19]. Therefore, nutraceuticals affect inflammation 
which is a prominent agent for enhancing the progression 
of tumors [19]. We further discuss the role of berberine as 
a nutraceutical and its anti-tumor effects on CRC molecular 
aspects and cell signaling pathways.
Colorectal cancer risk and preventive factors
Based on a study on twins, inheritable factors can cause 
about 35% of CRC risk [21]. Genetic factors playing a role 
in this cancer are not well-understood yet except for the 
hereditary types like familial adenomatous polyposis and 
hereditary non-polyposis colon cancer (Lynch syndrome) 
[21]. Moreover, a small association between single nucleo-
tide polymorphisms (SNPs) and CRC risk is suggested by 
meta-analyses studies [21]. Findings suggest that overall 
incidence is higher in men compared to women [22]. Age 
and gender, two important factors involved in CRC, are 
accompanied by risk factors such as inflammatory bowel 
disease (IBD) [23], obesity [24], diabetes [25], smoking 
[26], immoderate consumption of alcohol [27], red and pro-
cessed meat consumption [28] and family history of CRC 
[29]. Frequently, these factors happen at the same time and 
interact with one another. The role of infectious agents like 
Helicobacter pylori has been investigated in some novel 
studies [30]. There are several ways to prevent this cancer 
including hormone replacement therapy [31], aspirin [32], 
physical activity [33] and removing precancerous lesions 
with the help of endoscopy [34, 35]. Furthermore, evidence 
has shown that consumption of certain foods can prevent 
CRC including fish [36], dairy products [37], whole grains 
[38], fruit, vegetables and cereal fiber [39].
Berberine effects on different health 
conditions
An ammonium salt from the protoberberine group of isoqui-
noline alkaloids called berberine has vast pharmacological 
effects such as antimicrobial, antidiabetic and anti-tumor 
functions [40, 41]. Several plants have been found to have 
berberine including Berberis (e.g. Berberis aquifolium, 
Berberis vulgaris, Berberis aristata), Hydrastis canadensis, 
Xanthorhiza simplicissima, Phellodendron amurense, Coptis 
chinensis, Tinospora cordifolia, Argemone mexicana, and 
Eschscholzia californica [40]. Berberine has shown anti-
inflammatory and antioxidant properties in vitro [42]. It has 
demonstrated protective characteristics such as neuropro-
tective and cardiovascular protective within animal models 
[43, 44]. Moreover, numerous studies present that berberine 
decreases lipid levels and improves resistance to insulin in 
humans [40]. In this review, we focus on multiple roles of 
berberine in CRC tumor development such as inducing pro-
grammed cell death (both caspase-dependent and caspase-
independent), regulating microRNAs (miRNAs), controlling 
signaling pathways (Pin1/beta-catenin/cyclinD1 pathway, 
Wnt/β-catenin pathway, COX-2/PGE2- JAK2/STAT3 path-
way and IL-6/STAT3/NF-κB pathway), and acting as an 
anti-inflammatory and antioxidant agent.
Berberine‑induced cell death in CRC 
One of the well-known types of programmed cell death is 
apoptosis which happens in a caspase-dependent manner 
[45]. There are two pathways regulating caspase-depend-
ent apoptosis, extrinsic and intrinsic [45]. The former 
one is “death-receptor-mediated” and the latter one is 
“mitochondrial-mediated” [45]. An alternative mitochon-
drial route which is caspase-independent is another way 
that programmed cell death can occur [46]. What leads to 
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this process is the loss of mitochondrial function causing 
caspase-independent cell death by the release of mitochon-
drial proteins [47]. Berberine has been observed to induce 
apoptosis in colon cancer cells with many different mecha-
nisms. One of these mechanisms is through the caspase 3 
and caspase 8 activation as well as cleavage of poly ADP-
ribose polymerase (PARP) [48]. Meanwhile, it remarkably 
reduces c-IAP1, Bcl-2, and Bcl-(XL) expressions which 
are anti-apoptotic factors [48]. Berberine-induced apop-
tosis leads to JNK and P38 MAPK phosphorylation and 
formation of reactive oxygen species (ROS) [48]. Besides, 
activation of JNK and p38 signaling modulators in berber-
ine-induced apoptosis causes an increase in phospho-c-
Jun, FasL, and t-BID cellular levels [48].
Berberine activates a metabolic regulator called AMP-
activated protein kinase (AMPK), [49]. Mammalian target 
of rapamycin (mTOR), a downstream target of AMPK, is 
suppressed by berberine [49]. In vitro, berberine leads to 
a reduction in cyclin D1 and survivin expression, NF-κB 
activity inhibition, an increase in caspase 3 cleavage and 
induction of p53 phosphorylation [49]. Also, berberine 
results in AMPK activation, mTOR suppression, p65 phos-
phorylation and caspase 3 cleavage activation in vivo [49]. 
In Dai et al. [50] study, it is observed that when treating 
cells with berberine, lncRNA cancer susceptibility candi-
date 2 (CASC2) was up-regulated. Silencing the lncRNA 
CASC2 led to the suppression of apoptosis which was 
induced by berberine [50]. Thus, this lncRNA is a cru-
cial element for berberine-induced apoptosis. LncRNA 
CASC2 acts as a tumor suppressor in different cancers 
and makes a suppressing effect on Bcl-2 protein level [50]. 
Since it is shown that lncRNA CASC2 regulates expres-
sion of Bcl-2 protein, but it doesn’t affect its mRNA levels, 
it can be concluded that its regulatory effect is at the post-
transcriptional level [50]. Altogether, berberine induces 
apoptosis mediated by lncRNA CASC2 and has anti-tumor 
effects such as suppressing tumor cells viability [50]. In 
an in vitro study on the mouse immorto-Min colonic epi-
thelial (IMCE) cells, administering berberine induced 
the release of apoptosis-inducing factor (AIF), caspase-
independent cell death mediator, in a manner which was 
dependent on ROS production [51]. Additionally, berber-
ine stimulates the release of cathepsin B and activation of 
PARP which are two targets of ROS production in cells 
[51]. As a result, AIF activation leads to caspase-inde-
pendent cell death in colon cancer tissues [51]. Since nor-
mal colon epithelial cells do not show such a vulnerabil-
ity to berberine-induced cell death, this anti-proliferative 
feature of berberine is specific for colon tumor cells [51].
Berberine and miRNA
Based on recent evidence, miRNA changes are responsible 
for the formation and progression of various human cancers 
[52, 53]. Location of miRNA genes in cancer-related genomic 
regions, epigenetic processes and changes in miRNA process-
ing machinery are some of the explanations about why these 
genes are differentially expressed in malignancies compared 
with normal tissues [54]. Due to the unique miRNA-expres-
sion features of tumors, miRNAs can be used in different 
ways including diagnosis, staging, progression, prognosis, 
and response to treatment [54]. Berberine regulatory effects 
on miRNAs which are dysregulated in malignancies make it 
a potential agent for treating cancers. Multiple myeloma [55], 
ovarian cancer [56], endometrial cancer [57] and CRC [58] 
are some examples of cancers in which berberine can affect 
miRNAs.
Berberine is capable of changing the expression of vari-
ous genes which are involved in the apoptosis regulation, 
progression of cell cycle and drug resistance by the TP53 
stimulation and miRNAs expression [59]. Compared to nor-
mal tissues, mi-429 has a higher expression level in CRC 
which implies that it is an oncomir [60]. While berberine 
inhibits the E-cadherin and partitioning defective 3 (Par-3), 
with berberine and evodiamine treatment, there is a reduc-
tion in miR-429 levels in the tumor cells [58]. Berberine and 
evodiamine have demonstrated a notable impact on DNMTs 
expression and target miRNAs during colon cancer forma-
tion [58]. Their effect on miR-29a expression was more clear 
which indicates that berberine and evodiamine mediate the 
DNMTs expression and miRNAs through a process engaging 
various factors targeting [61]. During the progress of CRC, 
expression of microRNA-296 (miR-296) is lost progressively 
and is associated with metastasis [62]. In NVP-AUY922 treat-
ment, drug resistance has been observed as a side effect due 
to the higher expression levels of survivin [63]. Berberine 
decreases the growth of the normally resistant cells when it is 
used in combination with NVP-AUY922 which is an HSP-90 
suppressor [63]. Berberine exerts this function by inhibiting 
Pin1/beta-catenin/cyclinD1 signaling pathway mediated by 
miR-296-5p and suppressing the expression of CDK4 [63]. 
As we mentioned above, Dai et al. [50] concluded that ber-
berine upregulates the CASC2 which is critical for anti-tumor 
effects of berberine. Meanwhile, it is suggested that CASC2 
plays its anti-tumor role by acting as competing endogenous 
RNA through miR-18a sponging in CRC [64].
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Berberine role as an RXRα in cell signal 
pathway
One of the possible reasons for the anti-tumor charac-
teristics of berberine is its strong binding to DNA which 
may result in epigenetic changes [65]. A reduction in the 
number and the size of colorectal polyps has been seen 
in patients who suffered familial adenomatous polyposis 
with the oral administration of berberine soon after the 
polypectomy [66]. This effect was associated with sig-
nificant diminution in the expression of cyclin D1 [66]. 
Cyclin D1 up-regulation is linked with tumorigenesis of 
the colon and its metastasis which is due to the activa-
tion of Wnt/β-catenin signaling pathway [67]. Whereas, 
berberine has shown preventive effects on the β-catenin 
pathway [67]. Wnt/β-catenin signaling pathway has a wide 
interaction with members of the nuclear receptor super-
family [68]. One of these members is retinoid X receptor 
α (RXRα) which has been indicated modulatory roles on 
the β-catenin signaling [69, 70]. Therefore, the unusual 
activation of the β-catenin pathway could be a result of 
abnormal RXRα function [71]. In fact, in colon tumor tis-
sues, abnormal alteration of RXRα protein is usually seen 
[72]. Moreover, RXRα genetic diversity is linked with the 
colorectal adenoma risk of recurrence [73]. Besides, in 
CRC tissues, excessive phosphorylation of RXRα occurs 
which is a cause to inhibition of RXRα transactivation 
[74]. Based on several findings investigating the role of 
RXRα agonists and factors binding to it, RXRα can be 
considered as a target for colon cancer treatments [71, 
75–77]. In addition, Ruan et al. [71] found that berber-
ine could be a novel RXRα activator. They gathered evi-
dence suggesting that binding of berberine to RXRα by a 
unique binding mechanism, which enhances the interac-
tion between RXRα and nuclear β-catenin, results in sup-
pression of β-catenin signaling both in vitro and in vivo 
animals [71].
Berberine and inflammation
There is an important association between chronic inflam-
mation and cancer progression [78]. 15–20% of all can-
cer-related deaths have been estimated to be related to 
inflammatory processes and underlying infections [79]. 
IBDs such as Crohn’s disease and Ulcerative colitis lead 
to a higher risk of colitis-associated CRCs which show 
poor prognoses [80, 81]. These findings imply that chronic 
inflammation in the gut could lead to the initiation of tum-
origenesis and promoting cancer development. Besides, 
the role of inflammatory cytokines and tumor-infiltrating 
immune cells has been indicated in CRC after the primary 
tumors development [82]. Innate immune cells (including 
macrophages, neutrophils, and dendritic cells) and adap-
tive immune cells (including T and B cells) are involved in 
the inflammation giving rise to the secretion of extremely 
genotoxic compounds, oxygen/ nitrogen reactive species 
[83]. In addition, immune cells result in the release of pro-
inflammatory cytokines such as interleukin (IL)-6, IL-8, 
IL-1β and tumor necrosis factor-α (TNF-α) and growth 
factors [84]. While these mediators are produced through 
various signaling pathways such as NF-κB, signal trans-
ducer and activator of transcription 3 (STAT3), PI3K/
AKT, and cyclooxygenase-2 (COX-2)/prostaglandin E2 
(PGE2), they have a role in multiple mechanisms such as 
proliferation, angiogenesis, invasion and metastasis [84].
Due to the similarities of inflammatory environment and 
tumor microenvironment, it is implied that the same agents 
are involved in the chronic intestinal inflammation and for-
mation of CRC [85]. Thus, there is a link between inflam-
matory mediators and prevalence of colorectal adenomas 
[85]. In a dose-dependent manner, COX-2 is inhibited by 
berberine at mRNA and protein level [86]. Besides, ber-
berine reduces COX-2 activity and the concentration of 
prostaglandin E2 [86]. These data suggest that berberine 
suppresses the growth and proliferation of human colon cell 
line, HT29 [86]. Another finding indicates that berberine 
decreases JAK2 and STAT3 phosphorylation as well as 
MMP-2/-9 expression [87]. The reduction in the JAK2/
STAT3 signaling is a consequent of attenuating the COX-2/
PGE2 expression [87]. As a result, berberine prevents the 
proliferation, invasion, and metastasis of CRC cells both 
in vitro and in vivo by down-regulation of COX-2/PGE2- 
JAK2/STAT3 signaling pathway [87]. Li et al. [88] found 
that berberine exerts its anti-proliferative effect by involving 
inflammatory response-driven EGFR signaling in order to 
prevent the further progress of colitis-associated CRC. In a 
recent study of ulcerative colitis, it is reported that treatment 
with berberine hydrochloride and sulphasalazine led to the 
suppression of IL-1, IL-1β, IL-6, IL-12, TNF-α, TGF-β, and 
IFN-γ and higher expression levels of IL-4 and IL-10 [89]. 
Biochemical analyses suggest a higher expression level of 
p-STAT3 and down-regulation of p-NF-κB (p65) [89]. Con-
sequently, the suppressing effect of berberine hydrochloride 
on IL-6/STAT3/NF-κB signaling pathway is the probable 
process by which berberine plays its anti-inflammatory role 
[89].
Antioxidative effects of berberine on CRC 
Oxidative stress affecting DNA sequences could lead to 
the CRC and results in the transformation of adenoma to 
carcinoma [90]. Several studies suggested that antioxidants 
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have positive impacts on CRC [91]. Although there is not 
enough evidence to confirm the exact effects of antioxidants 
on human CRC, antioxidant consumption is recommended 
to the patients having a history of CRC or IBD [90]. Gegen 
Qinlian is a decoction of Chinese medicinal herb which is 
proved to have beneficial effects in the ulcerative colitis [92]. 
Baicalin, glabridin, and berberine are some of the active 
components of Gegen Qinlian which are indicated to reduce 
the inflammation and oxidative stress in vivo and in vitro 
[93–95]. Li  et al. [96] investigated the effect of Gegen 
Qinlian on mice ulcerative colitis and concluded that this 
decoction decreases inflammation and oxidative stress as 
evidenced by a reduction in the activity of myeloperoxidase 
and malondialdehyde level and increase in the content of 
glutathione in vivo. Other findings also show that berberine 
decreases myeloperoxidase levels as well as increases the 
levels of superoxide dismutase and catalase [97]. Myelop-
eroxidase, superoxide dismutase, and catalase are enzymes 
which play important roles in inflammation and oxidative 
stress [98–102]. While myeloperoxidase is an indicator of 
oxidative damage, superoxide dismutase and catalase serve 
as antioxidants [103]. Cytokines, growth factors and oxida-
tive stress are activators of STAT3 which is a transcriptional 
activator [104, 105]. Berberine has been shown to prevent 
the phosphorylation of STAT3 in mice with colitis suggest-
ing that the anti-inflammatory and antioxidant effects of 
berberine in colitis are possibly related to the reduction of 
p-STAT3 [97].
Conclusions
Berberine is an isoquinoline alkaloid which is found in 
several plants such as Berberis, Xanthorhiza simplicis-
sima, Phellodendron amurense, Coptis chinensis, and 
Tinospora cordifolia. Berberine has shown multiple bio-
activities such as improving insulin resistance and anti-
tumor properties as well as cardiovascular protective and 
neuroprotective features. Berberine anti-tumor charac-
teristics encompass preventing tumor growth, invasion, 
migration and metastasis. Related to CRC, berberine has 
demonstrated many functions which may lead to preven-
tion or treatment of this cancer. For instance, berberine 
induces both caspase-dependent and caspase-independent 
programmed cell death, regulates miRNAs, and involves 
different signaling pathways. Moreover, berberine attenu-
ates oxidative stress and inhibits inflammation. In order 
to exert its functions, berberine makes various effects on 
proteins (c-IAP1, Bcl-2, and Bcl-XL), enzymes (PARP, 
DNMT), and miRNAs (miR-429, miR-296) (Table  1; 
Fig. 1). Altogether, there is a necessity for further com-
prehensive investigations with the purpose of clarifying 
berberine roles in CRC. Hopefully, berberine can be used 
Table 1  Experimental studies that investigated the apoptosis-inducing role of berberine in CRC 
Dosage Treatment duration Function Type of cell Study model References
40 μM 48 h Induces apoptosis, upregulates 
LncRNA CASC2
HT29 In vitro [50]
50 µM and 100 µM 18 h Induces caspase-independent cell 
death, stimulating AIF
IMCE In vitro [51]
50 µM 24 h Induces caspase 3- and caspase 
8-dependent cell death
SW620 In vitro [48]
Up to 100 μmol/L 24, 48 and 72 h Actives AMPK, increases caspase 
3 cleavage
HCT116, SW480 In vivo, in vitro [49]
10 µM 24 h Induces apoptosis mediated by 
mitochondria central roll
HCT116 In vitro [106]
120 and 240 mg/kg Five times a week up to the 20th 
week
Induces caspase 3-dependent 
apoptosis
HCT116 In vitro [107]
10 µM 48 h Inhibits NF-κB activation, enhances 
CPT-11-induced apoptosis
HCT116 In vitro [108]
25 μM 24 h Induces caspase 3- and caspase 
9-dependent apoptosis
SW480 In vitro [109]
10 μM and 50 µM 4 days and 2 days, respectively Induces apoptosis in which NAG-1 
and ATF3 expression is involved, 
reduces cell proliferation
HCT116 In vitro [110]
– – Induces apoptosis which possibly 
involves death receptor pathway
HCT8 In vitro [111]
75 mg /Kg 15 days prior DMH intoxication 
and concurrently with DMH over 
eight weeks
Induces apoptosis, ameliorates 1,2 
Di methyl hydrazine induced 
colon cancer
– In vitro [112]
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as a novel multi-targeting therapeutic agent instead of the 
current single-targeted drugs.
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